Avaliação da judicialização de medicamentos antineoplásicos no Estado do Rio Grande do Norte

• Ano de defesa: 2019
• Autor(a) principal: Coelho, Bruna Lorena Alves
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal do Rio Grande do Norte; Brasil; UFRN; PROGRAMA DE PÓS-GRADUAÇÃO EM SAÚDE COLETIVA
• Palavras-chave em Português: Direito à saúde; Judicialização da saúde; Judicialização do acesso a medicamentos; CNPQ::CIENCIAS DA SAUDE::SAUDE COLETIVA
• Link de acesso: https://repositorio.ufrn.br/handle/123456789/63136

The advances of health policies, in the Federal Constitution of 1988, are unquestionable. However, deficiencies in the Unified Health System made it difficult to meet the population health needs. Changes in the population epidemiological profile add to technological advances causes increasing of the lawsuit for healthcare. This practice is called Judicialization of health. Among the demands in the area of health the processes that call for medicines stand out and in this segment one of the biggest financial impacts is linked to the antineoplastic drugs. This is a descriptive, exploratory and documentary study of lawsuits claiming antineoplastic drugs that have the state of Rio Grande do Norte as sole defendant or in a regime of solidarity with the other entities of the federation. The objective of this study is to evaluate the judicialization of antineoplastic drugs involving the State of Rio Grande do Norte from 2013 to 2017. The socio-demographic characteristics of the author; Procedural characteristics of lawsuits; Medical-sanitary characteristics of the actions and administrative political characteristics of the actions were evaluated. The data were analyzed by indicators taken from the manual "Evaluation indicators and monitoring of drug lawsuits". The results show that the global expenditure of the defined temporal scope was R $ 19,266,268.30, with a larger number of cases coming from the metropolitan health region (39.5%) and Mossoró (28.5%), (44.7%), female, between 61 and 70 years (31.4%), with a more predominant diagnosis of breast cancer (19.3%). Represented by public defenders (53.7%). Most of the individuals (81.2%) had access to the medication, which had a purchase made mostly by the author of the action (81%). The phenomenon of the judicialization of antineoplastics in Rio Grande evidences the need to develop efficient means of screening to ascertain the amount of resources handled by the judicialization, and a greater dialogue among those involved, to draw up assertive strategies for financial management of health resources.